Placing of New Ordinary Shares


 

TIDMHML 
 
RNS Number : 5042M 
Henderson Morley PLC 
30 January 2009 
 
30 January 2009 
 
 
Henderson Morley PLC 
(the "Company") 
 
Placing of new ordinary shares 
 
 
Henderson Morley plc, the AIM quoted biotechnology company, announces that the 
Board has, today, issued and allotted a total of 146 million new ordinary shares 
through a Placing by Hybridan LLP to Institutional shareholders and other 
investors at 0.2 pence per share, raising GBP292,000 (gross) for the Company. 
 
Andrew Knight and Dr Ian Pardoe, Directors of the Company, have each subscribed 
GBP50,000 for 25 million new ordinary shares as part of the Placing. It is 
intended that these shares will be held in their respective Self Invested 
Pension Plans. The Directors, other than Messrs Knight and Pardoe, having 
consulted with the Company's nominated adviser, believe that the terms of this 
transaction are fair and reasonable insofar as shareholders are concerned. 
 
Following the Placing A Knight and Dr I Pardoe will own 111,153,764 and 
74,727,751 shares respectively, representing 15.41% and 10.36% respectively of 
the Company's enlarged issued share capital of 721,261,963 shares in issue. 
 
Mr Michael Dunne has also subscribed GBP20,000 for 10 million shares and is now 
interested in 6.44% of the Company's enlarged issued share capital. 
 
The Placing is to fund additional working capital for the Company. 
 
Application has been made for the new shares to be admitted to AIM and trading 
in the new shares is expected to commence on 4 February 2009. 
 
=-ENDS-- 
 
 
ENQUIRIES: 
 
HENDERSON MORLEY PLC                                     0121 442 4600 
Andrew Knight, Chairman 
 
BISHOPSGATE COMMUNICATIONS LTD       0207 562 3350 
(Public Relations) 
Maxine Barnes 
Nick Rome 
 
BREWIN DOLPHIN INVESTMENT BANKING 0113 241 0126 
(Nominated Adviser) 
Neil Baldwin 
 
 
HYBRIDAN LLP 0203 159 5085 
(Broker) 
Claire Noyce/Stephen Austin 
 
 
Notes to Editors: 
 
Henderson Morley was founded in 1996 with the objective of developing its anti 
viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform 
and has been developed in-house and HML wholly owns the patent IPR. 
 
Further information on Henderson Morley plc can be accessed through the 
Company's website at www.henderson-morley.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 IOEBLMLTMMMTBLL

Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024